| Zhang, Xiang Y |
| Recruiting | 3 | 455 | RoW | Paraaortic prophylactic irradiation and pelvic definitive concurrent chemoradiation, Pelvic definitive concurrent chemoradiation | Zhejiang Cancer Hospital | Cervical Cancer | 08/28 | 08/30 | | |
NCT05234905: H101 Combined With Camrelizumab for Recurrent Cervical Cancer |
|
|
| Not yet recruiting | 2 | 55 | RoW | Recombinant human adenovirus type 5＋Camrelizumab, H101＋Camrelizumab | Zhejiang Cancer Hospital | Uterine Cervical Neoplasms, Oncolytic Virotherapy, Camrelizumab | 06/23 | 12/24 | | |
NCT05559450: Blinatumomab as a Bridge to Allo-HSCT in HR BCP-ALL |
|
|
| Recruiting | 2 | 80 | RoW | Blinatumomab, Conventional therapy | The First Affiliated Hospital of Soochow University, Fujian Medical University Union Hospital, Zhongda Hospital, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, The First People's Hospital of Changzhou, Wuxi People's Hospital, First Affiliated Hospital of Wannan Medical College | B-cell Acute Lymphoblastic Leukemia | 01/24 | 01/26 | | |
NCT05112991: Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer |
|
|
| Recruiting | 2 | 108 | RoW | Envafolimab+Lenvatinib, Envafolimab | 3D Medicines (Sichuan) Co., Ltd. | Advanced Endometrial Cancer | 03/25 | 10/25 | | |
| Active, not recruiting | 1/2 | 196 | RoW | CAR T-cell therapy | The First Affiliated Hospital of Soochow University, Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd, The Second People's Hospital of Huai'an, Third Military Medical University | Acute Lymphoblastic Leukemia with Failed Remission | 08/24 | 12/25 | | |
| Not yet recruiting | N/A | 15 | RoW | colonic infusion | Qilu Hospital of Shandong University | Gastrointestinal Hormones | 07/22 | 08/22 | | |
NCT05159323: Quantitative Assessment of Diffusion Spectrum Imaging in Breast Cancer |
|
|
| Recruiting | N/A | 64 | RoW | Diffusion Spectrum Imaging | Xiang Zhang | Breast Carcinoma; Magnetic Resonance Imaging; Diffusion Spectrum Imaging | 08/22 | 08/22 | | |
NCT05552014: Study on the Efficacy Mechanism of Natural Psychotherapy for Neurosis |
|
|
| Recruiting | N/A | 80 | RoW | Natural Psychotherapy, Mental Health Education | Beijing HuiLongGuan Hospital | Obsessive-Compulsive Disorder | 12/25 | 12/25 | | |
NCT05129774: Chemoradiotherapy Sequenced Radical Surgery for Colorectal Cancer With PALNM |
|
|
| Not yet recruiting | N/A | 40 | RoW | Radical surgery with PALND, Radical surgery without PALND | Qilu Hospital of Shandong University | Colorectal Neoplasms Malignant, Lymph Node Excision, Chemoradiotherapy | 01/24 | 01/27 | | |
NCT06344923: Peritoneum and Anterior Rectus Sheath Suturing and Ileostomy |
|
|
| Recruiting | N/A | 120 | RoW | Ileostomy with a support rod instead of the layer of peritoneum and anterior rectus sheath suturing, Ileostomy with the layer of the peritoneum and anterior rectus sheath suturing | Qilu Hospital of Shandong University | Ileostomy - Stoma, Rectal Neoplasms | 05/25 | 09/25 | | |
NCT05502354: CRP-guided Transanal Drainage Removal After Rectal Surgery |
|
|
| Recruiting | N/A | 250 | RoW | removal of transanal drainage tube | Qilu Hospital of Shandong University | Rectal Cancer, Anastomotic Leak | 12/24 | 02/25 | | |
NCT06841952: Study of Tretinoin Capsules in Combination With Azacitidine and Venetoclax in Treatment Naïve Participants With Acute Myeloid Leukemia |
|
|
| Not yet recruiting | N/A | 158 | RoW | ATRA+Venetoclax+Azacitidine, Chemotherapy drug | The First Affiliated Hospital of Soochow University | AML, Adult | 12/28 | 12/30 | | |
| Recruiting | N/A | 300 | RoW | Brachytherapy | Zhejiang Cancer Hospital | Brachytherapy, Uterine Cervical Neoplasms, Uterine Neoplasms, Vulvar Cancer, Vaginal Cancer, Ovarian Neoplasms, Gynecologic Neoplasm | 12/24 | 12/27 | | |
| Recruiting | N/A | 500 | RoW | collection data | The First Affiliated Hospital of Soochow University | TTP - Thrombotic Thrombocytopenic Purpura | 10/27 | 10/28 | | |
| Chen, Jia Ching |
| Completed | 4 | 310 | RoW | Caffeine Citrate 20 MG/1 ML Intravenous Solution [CAFCIT] | Children's Hospital of Chongqing Medical University | Apnea of Prematurity, Caffeine, Weaning Oxygen, Medicine Regimen | 10/23 | 10/23 | | |
NCT02323022: Idarubicin Plus Cytarabine (IA) vs IA Plus Cladribine (IAC) as Induction Regimen to Treat Initially Diagnosed Acute Myeloid Leukemia (AML) |
|
|
| Completed | 3 | 618 | RoW | IAC regimen, IA regimen | The First Affiliated Hospital of Soochow University | Acute Myeloid Leukemia | 03/20 | 01/22 | | |
NCT03719534: Haplo HCT vs Haplo-cord HCT for Patients With AML |
|
|
| Completed | 3 | 134 | RoW | haplo-HCT, haplo-cord HCT | The First Affiliated Hospital of Soochow University, Zhejiang University, The Second People's Hospital of Huai'an, Soochow Hopes Hematology Hospital, Hygeia Suzhou Yongding Hospital | Hematopoietic Stem Cell Transplantation, Haplo-identical Donor, Cord Blood Unit, Acute Myeloid Leukemia | 12/22 | 03/23 | | |
| Recruiting | 3 | 8000 | US | Azithromycin Injection, Placebo, Standard of Care Preoperative antibiotics | The George Washington University Biostatistics Center, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), University of Alabama at Birmingham | Obstetrical Complications, Labor and Delivery Complication, Cesarean Delivery | 11/27 | 03/28 | | |
PROSPECT, NCT02518594: A Trial of Pessary and Progesterone for Preterm Prevention in Twin Gestation With a Short Cervix |
|
|
| Active, not recruiting | 3 | 437 | US | Vaginal progesterone, Prometrium, Placebo, Arabin Pessary | The George Washington University Biostatistics Center, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Short Cervical Length | 12/24 | 04/25 | | |
| Active, not recruiting | 1/2 | 196 | RoW | CAR T-cell therapy | The First Affiliated Hospital of Soochow University, Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd, The Second People's Hospital of Huai'an, Third Military Medical University | Acute Lymphoblastic Leukemia with Failed Remission | 08/24 | 12/25 | | |
NCT04686929: Abatacept s.c. for aGVHD Prevention in Haplo-HCT |
|
|
| Recruiting | 1/2 | 29 | RoW | Abatacept s.c. | The First Affiliated Hospital of Soochow University | Abatacept, Acute-graft-versus-host Disease, Haplo-identical HCT, Prevention | 06/23 | 12/23 | | |
NCT03487185: Continuous Positive Airway Pressure (CPAP) for Sleep Apnea in Pregnancy |
|
|
| Recruiting | N/A | 1500 | US | Continuous Positive Airway Pressure, CPAP, Sleep Advice Control | The George Washington University Biostatistics Center, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Heart, Lung, and Blood Institute (NHLBI) | Obstructive Sleep Apnea of Adult, Preeclampsia, Obstetrical Complications | 12/26 | 12/26 | | |
NCT05409482: A Real-world Study of Camrelizumab Combined With Apatinib Mesylate in Unresectable Hepatocellular Carcinoma |
|
|
| Recruiting | N/A | 300 | RoW | | Meng Chao Hepatobiliary Hospital of Fujian Medical University, Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Hepatocellular Carcinoma | 03/26 | 03/26 | | |
| Wu, Depei |
NCT02323022: Idarubicin Plus Cytarabine (IA) vs IA Plus Cladribine (IAC) as Induction Regimen to Treat Initially Diagnosed Acute Myeloid Leukemia (AML) |
|
|
| Completed | 3 | 618 | RoW | IAC regimen, IA regimen | The First Affiliated Hospital of Soochow University | Acute Myeloid Leukemia | 03/20 | 01/22 | | |
NCT03719534: Haplo HCT vs Haplo-cord HCT for Patients With AML |
|
|
| Completed | 3 | 134 | RoW | haplo-HCT, haplo-cord HCT | The First Affiliated Hospital of Soochow University, Zhejiang University, The Second People's Hospital of Huai'an, Soochow Hopes Hematology Hospital, Hygeia Suzhou Yongding Hospital | Hematopoietic Stem Cell Transplantation, Haplo-identical Donor, Cord Blood Unit, Acute Myeloid Leukemia | 12/22 | 03/23 | | |
NCT05051891: A Randomized, Open-label, Multi-center, Phase III Study of Orelabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) vs. R-CHOP Alone in Patients With Treatment-naїve Mantle Cell Lymphoma |
|
|
| Recruiting | 3 | 356 | RoW | Orelabrutinib and R-CHOP, R-CHOP | Beijing InnoCare Pharma Tech Co., Ltd. | Treatment-naїve Mantle Cell Lymphoma | 12/24 | 12/27 | | |
NCT04547049: A Study Comparing Haploidentical Hematopoietic Stem Cell Transplantations (HSCTs) from Young Non-first-degree and Older First-degree Donors in Hematological Malignancies |
|
|
| Recruiting | 3 | 160 | RoW | Cytarabine, Busulfan, Cyclophosphamide, Me-CCNU, Rabbit antithymocyte globulin, Allogeneic HSCT, Cyclosporin A, Mycophenolate Mofetil, MTX | First Affiliated Hospital of Zhejiang University | Leukemia | 09/25 | 12/25 | | |
| Recruiting | 2/3 | 120 | RoW | Eltrombopag 25 MG Oral Tablet, TPO-RA, Supportive care, support | The First Affiliated Hospital of Soochow University | Stem Cell Transplant Complications | 07/25 | 07/27 | | |
NCT04539444: A Study of CD19/22 CART Cells Combined With PD-1 Inhibitor in Relapsed/Refractory B-cell Lymphoma |
|
|
| Recruiting | 2 | 10 | RoW | CD19/22 CART, Tislelizumab, PD-1 inhibitor | The First Affiliated Hospital of Soochow University, Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd | Relapsed Non Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma | 02/22 | 02/23 | | |
NCT04930562: Efficacy and Safety of BN101 in Subjects With Chronic Graft Versus Host Disease (cGVHD) |
|
|
| Completed | 2 | 30 | RoW | BN101, belumosudil, KD025 | BioNova Pharmaceuticals (Shanghai) LTD. | GVHD, Chronic | 06/22 | 12/22 | | |
ABSK021-201, NCT06186804: A Phase II Study Evaluating the Efficacy and Safety of ABSK021 (Pimicotinib)) in the Treatment of cGvHD Chronic Graft Versus Host Disease (cGvHD) |
|
|
| Enrolling by invitation | 2 | 64 | RoW | ABSK021 | Abbisko Therapeutics Co, Ltd | cGvHD | 10/26 | 12/26 | | |
| Recruiting | 2 | 20 | RoW | Humanized CD7 CAR-T cells | The First Affiliated Hospital of Soochow University, PersonGen BioTherapeutics (Suzhou) Co., Ltd., The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Affiliated Hospital of Jiangnan University, The Affiliated Zhongshan Hospital of Dalian University, The First Affiliated Hospital of Dalian Medical University | Refractory and Relapsed T Cell Lymphoma | 08/23 | 08/24 | | |
NCT05510505: GVHD Prophylaxis by Addition of CD20 Monoclonal Antibody to the Conditioning Regimen in SAA With Treatment of Allo-HSCT |
|
|
| Recruiting | 2 | 100 | RoW | CD20 monoclonal antibody, allogeneic hematopoietic stem cell transplantation, ATG | The First Affiliated Hospital of Soochow University | Aplastic Anemia | 09/23 | 12/25 | | |
NCT05182957: Clinical Study on Anti-PD-1 Plus Lenalidomide and Azacitidine in Relapsed/Refractory Peripheral T-cell Lymphoma |
|
|
| Recruiting | 2 | 40 | RoW | Anti-PD-1 monoclonal antibody, Anti-PD-1 antibody, Lenalidomide, Immunomodulator, Azacitidine, 5-Ladakamycin | The First Affiliated Hospital of Soochow University | Relapsed/Refractory Peripheral T-cell Lymphoma | 12/23 | 12/23 | | |
NCT05322330: Clinical Study of XPO-1 Inhibitors Plus CAR-T Cells in Relapsed Refractory B-cell Non-Hodgkin's Lymphoma |
|
|
| Recruiting | 2 | 20 | RoW | Selinexor, XPO-1 Inhibitor, Flu, Fludarabine, CTX, Cyclophosphamide, CAR-T, Chimeric antigen receptor-modified T (CAR-T) cell therapy | The First Affiliated Hospital of Soochow University, West China Hospital, The General Hospital of Western Theater Command PLA, The Affiliated People's Hospital of Ningbo University Ningbo Yinzhou People's Hospital Community, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Yixing People's Hospital, Affiliated Hospital of Jiangnan University, Wuxi Second People's Hospital | Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma | 02/24 | 02/24 | | |
NCT06394011: Study of VA Combined With HAAG Regimen in Newly Diagnosed Intermediate and High-risk AML Patients |
|
|
| Recruiting | 2 | 60 | RoW | venetoclax, azacitidine and HAAG regimen | The First Affiliated Hospital of Soochow University | Intermediate Risk Acute Myeloid Leukemia, High Risk Acute Myeloid Leukemia | 05/26 | 12/26 | | |
NCT05241106: A Study of HYML-122 in Patients With FLT3 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML) |
|
|
| Recruiting | 2 | 15 | RoW | HYML-122 | Tarapeutics Science Inc. | Relapsed or Refractory Acute Myeloid Leukemia (AML) | 12/25 | 06/26 | | |
NCT05241093: A Study of HYML-122 and Cytarabine in Patients With FLT3 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML) |
|
|
| Recruiting | 2 | 18 | RoW | HYML-122; cytarabine | Tarapeutics Science Inc. | Relapsed or Refractory Acute Myeloid Leukemia (AML) | 12/24 | 06/25 | | |
NCT06367114: Clinical Trial of ssCART-19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia (Including Central Nervous System Infiltration) |
|
|
| Not yet recruiting | 2 | 50 | RoW | ssCART-19, Fludarabine, Cyclophosphamide | Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd, The First Affiliated Hospital of Soochow University, Peking University People's Hospital | Relapsed or Refractory Acute Lymphoblastic Leukemia | 09/24 | 12/25 | | |
NCT06093841: Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL |
|
|
| Active, not recruiting | 2 | 46 | RoW | Relmacabtagene Autoleucel, JWCAR029, Fludarabine, Cyclophosphamide | Shanghai Ming Ju Biotechnology Co., Ltd. | Lymphoma, Large B-Cell, Diffuse, Follicular Lymphoma Grade 3B, High-grade B-cell Lymphoma, Mediastinal B-Cell Diffuse Large Cell Lymphoma | 01/24 | 11/29 | | |
NCT06078306: CD19CD22 CAR-T Therapy in Patients With High-Risk B Acute Lymphoblastic Leukemia (B-ALL). |
|
|
| Recruiting | 2 | 20 | RoW | Azacitidine Injection, Azacitidine, Venetoclax, ABT-199, CD19CD22 CAR-T, GDC-0199 | The First Affiliated Hospital of Soochow University | B Acute Lymphoblastic Leukemia, Ph-Negative ALL, High Risk Acute Lymphoblastic Leukemia | 09/24 | 09/25 | | |
NCT05809167: Venetoclax+Azacytidine+Modified BUCY Conditioning Regimen for Acute Lymphoblastic Leukemia Undergoing Allo-HSCT |
|
|
| Recruiting | 2 | 55 | RoW | VEN+AZA+Modified BUCY | The First Affiliated Hospital of Soochow University | Allogeneic Hematopoietic Stem Cell Transplantation, Acute Lymphoblastic Leukemia | 01/25 | 01/26 | | |
NCT05823714: Venetoclax+Azacytidine+Modified BUCY Conditioning Regimen for Acute Myeloid Leukemia and Myelodysplastic Syndromes Undergoing Allo-HSCT |
|
|
| Recruiting | 2 | 70 | RoW | VEN+AZA+Modified BUCY | The First Affiliated Hospital of Soochow University | Allogeneic Hematopoietic Stem Cell Transplantation, Acute Myeloid Leukemia, Myelodysplastic Syndrome | 01/25 | 01/26 | | |
NCT05312476: Clinical Study on CAR-T Targeting Igβ Targets in Refractory Relapsed Non-Hodgkin's Lymphoma |
|
|
| Recruiting | 2 | 12 | RoW | Chimeric Antigen Receptor T Cells (CAR-T) Targeting Igβ Targets, Chimeric antigen receptor-modified T (CAR-T) cell therapy | The First Affiliated Hospital of Soochow University | Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma | 02/25 | 02/25 | | |
NCT04835870: Zanubrutinib Plus R-CHOP for Patients With Newly Diagnosed Untreated Non-GCB DLBCL |
|
|
| Recruiting | 2 | 78 | RoW | Zanubrutinib, BTK inhibitors, Rituximab, MabThera, Cyclophosphamide, CTX, Doxorubicin, ADM, Vincristine, VCR, Prednisone, Prednisonum | The First Affiliated Hospital of Soochow University | Non-GCB/ABC Diffuse Large B-Cell Lymphoma | 10/25 | 10/25 | | |
| Active, not recruiting | 1/2 | 196 | RoW | CAR T-cell therapy | The First Affiliated Hospital of Soochow University, Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd, The Second People's Hospital of Huai'an, Third Military Medical University | Acute Lymphoblastic Leukemia with Failed Remission | 08/24 | 12/25 | | |
NCT03455972: Study of T Cells Targeting CD19/BCMA (CART-19/BCMA) for High Risk Multiple Myeloma Followed With Auto-HSCT |
|
|
| Recruiting | 1/2 | 15 | RoW | anti-CD19 and anti-BCMA CAR, Immunomodulatory drugs, IMiDs | The First Affiliated Hospital of Soochow University | Safety and Efficacy | 12/21 | 12/23 | | |
| Recruiting | 1/2 | 190 | RoW | AK117, Azacitidine | Akeso | Myelodysplastic Syndrome | 05/23 | 05/24 | | |
NCT04941404: A Study of TQ05105 Tablets in Subjects With Glucocorticoid-Refractory Acute Graft-Versus-Host Disease (aGVHD) |
|
|
| Active, not recruiting | 1/2 | 13 | RoW | TQ05105 tablets | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Glucocorticoid-Refractory aGVHD | 07/23 | 12/24 | | |
NCT05140616: Study of Chidamide for Steroid-resistant/Steroid-dependent Severe cGVHD |
|
|
| Recruiting | 1/2 | 20 | RoW | Chidamide | The First Affiliated Hospital of Soochow University | Safety and Efficacy | 05/24 | 05/24 | | |
NCT04485052: Efficacy and Safety Evaluation of IBI188 in Combination With Demethylating Agents in Treatment of Patients With Acute Myeloid Leukemia |
|
|
| Suspended | 1/2 | 222 | RoW | IBI188, Azacitidine, Decitabine | Innovent Biologics (Suzhou) Co. Ltd. | Acute Myeloid Leukemia | 06/24 | 12/24 | | |
NCT05381662: CD19 Chimeric Antigen Receptors and CD19 Positive Feeder T Cells as a Leukemia Consolidation Treatment |
|
|
| Recruiting | 1/2 | 10 | RoW | CD19 CAR-T cells and CD19 positive feeder T cells | Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd, The First Affiliated Hospital of Soochow University | Acute Lymphoblastic Leukemia in Remission | 08/24 | 12/25 | | |
NCT05647512: Study of LM-305 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) and Other Plasma Cell Diseases |
|
|
| Withdrawn | 1/2 | 380 | NA | LM-305, Dexamethasone | LaNova Medicines Limited | Relapsed or Refractory Multiple Myeloma, Other Plasma Cell Diseases | 12/24 | 12/25 | | |
NCT05768529: Clinical Study of U16 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma |
|
|
| Recruiting | 1/2 | 100 | RoW | U16 | Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd | Relapsed or Refractory Non-Hodgkin's Lymphoma | 12/24 | 12/26 | | |
NCT06052813: A Study of BN104 in the Treatment of Acute Leukemia |
|
|
| Recruiting | 1/2 | 90 | RoW | BN104 | BioNova Pharmaceuticals (Shanghai) LTD. | ALL, Adult, AML, Adult | 06/26 | 06/27 | | |
NCT05148442: A Study Evaluating the Safety, Tolerability and Preliminary Efficacy of IBI322 in Subjects With Myeloid Tumor |
|
|
| Terminated | 1a/1b | 1 | RoW | IBI322 | Innovent Biologics (Suzhou) Co. Ltd. | Myeloid Tumor | 06/23 | 08/23 | | |
NCT05270928: Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Preliminary Efficacy of IBI346#CIBI346Y001# |
|
|
| Completed | 1 | 6 | RoW | IBI346 | The First Affiliated Hospital of Soochow University, Innovent Biologics (Suzhou) Co. Ltd. | Relapsed/Refractory Multiple Myeloma | 12/22 | 05/23 | | |
NCT06234904: Study of IBR733 Cell Injection in Acute Myeloid Leukemia |
|
|
| Not yet recruiting | 1 | 18 | RoW | IBR733 Cell Injection | Imbioray (Hangzhou) Biomedicine Co., Ltd., The First Affiliated Hospital of Soochow University | Acute Myeloid Leukemia | 02/25 | 08/25 | | |
NCT06696833: Allogeneic CD19-targeted CAR-γδT Cell Infusion Therapy in Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia |
|
|
| Recruiting | 1 | 18 | RoW | QH10304-BAL-01, Fludarabine, Cyclophosphamide | The First Affiliated Hospital of Soochow University | B-Cell Acute Lymphoblastic Leukemia, Adult | 12/25 | 12/25 | | |
MAPLE-1, NCT04260217: APG-2575 Single Agent or in Combination With Ibrutinib or Rituximab in Patients With Waldenström Macroglobulinemia |
|
|
| Completed | 1 | 46 | US, RoW | APG2575 400 mg, APG2575 600 mg, APG2575 800 mg | Ascentage Pharma Group Inc. | Waldenstrom Macroglobulinemia | 02/24 | 02/24 | | |
NCT05641259: A Study to Assess Safety and Preliminary Efficacy of LP-108 Combined With Azacitidine In Subjects With AML, MDS, CMML |
|
|
| Recruiting | 1 | 198 | RoW | LP-108, Azacitidine | Guangzhou Lupeng Pharmaceutical Company LTD. | Acute Myeloid Leukemia, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia | 12/24 | 12/25 | | |
| Recruiting | 1 | 20 | RoW | Treatment | The First Affiliated Hospital of Soochow University, Fundamenta Therapeutics, Ltd. | CAR, Refractory Acute Lymphoblastic Leukemia, Relapsed Adult ALL | 11/25 | 11/25 | | |
NCT05691153: ThisCART19A for B-NHL Relapsed After Auto-CAR T |
|
|
| Recruiting | 1 | 20 | RoW | ThisCART19A with Dose Level 1, ThisCART19A with 2×10^6 cells/kg, ThisCART19A with Dose Level 2, ThisCART19A with 3×10^6 cells/kg | The First Affiliated Hospital of Soochow University, Fundamenta Therapeutics, Ltd. | CAR, B Cell Lymphoma, Relapsed Non-Hodgkin Lymphoma | 11/25 | 11/25 | | |
NCT06142175: Relmacabtagene Autoleucel in Patients With LBCL |
|
|
| Recruiting | N/A | 200 | RoW | Relmacabtagene Autoleucel, JWCAR029 | Shanghai Ming Ju Biotechnology Co., Ltd. | Large B-cell Lymphoma | 12/24 | 12/24 | | |
NCT05587881: Clinical Study on the Impact of Covid-19 Vaccine on Allogeneic Hematopoietic Stem Cell Transplantation |
|
|
| Withdrawn | N/A | 400 | RoW | COVID-19 vaccine(donor), COVID-19 vaccine(patient) | The First Affiliated Hospital of Soochow University | Hematologic Diseases | 11/23 | 11/23 | | |
NCT03148743: Fecal Microbiota Transplantation in Gut aGVHD Treated |
|
|
| Recruiting | N/A | 50 | RoW | Fecal microbiota | The First Affiliated Hospital of Soochow University | Acute-graft-versus-host Disease | 12/25 | 12/25 | | |
| Recruiting | N/A | 100 | RoW | | The First Affiliated Hospital of Soochow University | Graft Versus Host Disease | 12/26 | 12/26 | | |
NCT06548958: A Single-Arm, Prospective Study of TBI+BUMEL as Conditioning for SCT2 in Patients With Malignant Hematologic Diseases |
|
|
| Recruiting | N/A | 40 | RoW | Second Stem Cell Transplantation (SCT2) | The First Affiliated Hospital of Soochow University | Malignant Hematological Diseases | 03/27 | 06/27 | | |
NCT05852028: A Real-world Study of Selinexor-based Regimens for Treatment of Non-Hodgkin Lymphoma |
|
|
| Recruiting | N/A | 250 | RoW | Selinexor, XPO1 inhibitor | Ruijin Hospital | Lymphoma, DLBCL, T Cell Lymphoma | 10/24 | 10/25 | | |
| Active, not recruiting | N/A | 482 | RoW | | Takeda | Multiple Myeloma, Neoplasms, Plasma Cell | 09/25 | 09/25 | | |
NCT04923789: A Study of ASCT Bridging CART Cell Therapy in Relapsed/Refractory B-cell Lymphoma |
|
|
| Recruiting | N/A | 60 | RoW | | The First Affiliated Hospital of Soochow University, Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd | Relapsed Non Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma | 03/22 | 03/23 | | |
| Sun, Aining |
| Active, not recruiting | 1/2 | 196 | RoW | CAR T-cell therapy | The First Affiliated Hospital of Soochow University, Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd, The Second People's Hospital of Huai'an, Third Military Medical University | Acute Lymphoblastic Leukemia with Failed Remission | 08/24 | 12/25 | | |
| Qiu, Huiying |
| Active, not recruiting | 3 | 245 | Europe, Canada, Japan, US, RoW | Ponatinib, Iclusig, Imatinib, Gleevec, Vincristine, Dexamethasone, Cytarabine, Methotrexate, Prednisone | Takeda | Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL) | 08/22 | 07/27 | | |
|
|
VHA, NCT05805098: Venetoclax Combined With Homoharringtonine and Cytarabine in Induction for AML |
|
|
| Recruiting | 2/3 | 60 | RoW | Venetoclax, VEN, Homoharringtonine, HHT, Cytarabine | The First Affiliated Hospital of Soochow University | Acute Myeloid Leukemia | 03/25 | 03/28 | | |
NCT05951855: Study of Selinexor Combined With Chidamide in Relapsed/Refractory Acute Leukemia (AML) Patients |
|
|
| Recruiting | 2 | 42 | RoW | Selinexor, X, Chidamide, C | The First Affiliated Hospital of Soochow University | Acute Myeloid Leukemia (Relapsed/Refractory) | 09/24 | 03/25 | | |
| Active, not recruiting | 1/2 | 196 | RoW | CAR T-cell therapy | The First Affiliated Hospital of Soochow University, Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd, The Second People's Hospital of Huai'an, Third Military Medical University | Acute Lymphoblastic Leukemia with Failed Remission | 08/24 | 12/25 | | |
| Tang, Xiaowen |
NCT05634915: Clinical Study of rATG Individualized Administration in Haploidentical Hematopoietic Stem Cell Transplantation |
|
|
| Recruiting | 4 | 90 | RoW | Individual ATG, ATG | The First Affiliated Hospital of Soochow University | Hematopoietic Stem Cell Transplantation, Acute Leukemia | 12/24 | 05/25 | | |
NCT04446130: Study of Decitabine Combined With HAAG Regimen in Newly Diagnosed ETP-ALL/LBL, T/M-MPAL and ALL/LBL With Myeloid or Stem Cell Markers Patients |
|
|
| Recruiting | 3 | 100 | RoW | Decitabine combined with HAAG Regimen | The First Affiliated Hospital of Soochow University, Henan Cancer Hospital, Shandong Provincial Hospital, Shenzhen People's Hospital, The First Affiliated Hospital of Anhui Medical University, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Changzhou No.2 People's Hospital, The Second People's Hospital of Huai'an | Induction Chemotherapy, Acute T-Lymphocytic Leukemia, T-cell Lymphoblastic Lymphoma Leukemia, T-cell/Myeloid Mixed Phenotype Acute Leukemia | 01/23 | 01/24 | | |
NCT04287660: Study of BiRd Regimen Combined With BCMA CAR T-cell Therapy in Newly Diagnosed Multiple Myeloma (MM) Patients |
|
|
| Recruiting | 3 | 20 | RoW | clarithromycin, lenalidomide, dexamethasone and autologous BCMA-directed CAR T-cells | The First Affiliated Hospital of Soochow University, Changshu Frist People's Hospital, Huai'an Second People's Hospital, Affiliated Hospital of Jiangnan University, Jiangsu Province Hospital of Traditional Chinese Medicine, Jiangyin People's Hospital, Jingjiang People's Hospital, The Third People's Hospital of Kunshan, Lianyungang Hospital Affiliated Bengbu Medical College, Suzhou Municipal Hospital, Zhangjiagang First People's Hospital, Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd, The First Affiliated Hospital with Nanjing Medical University, The first Affiliated Hospital of Nanjing University Medical School | Multiple Myeloma | 01/23 | 01/25 | | |
| Recruiting | 2 | 5 | RoW | autologous anti-BCMA chimeric antigen receptor T cells | The First Affiliated Hospital of Soochow University, Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd | ITP | 12/22 | 06/23 | | |
NCT05433532: Study of Azacitidine，Venetoclax，and Flumatinib in Newly Diagnosed Ph-positive Acute Leukemia and CML-AP/BP Patients |
|
|
| Completed | 2 | 20 | RoW | Azacitidine, Venetoclax, Flumatinib | The First Affiliated Hospital of Soochow University | Philadelphia Chromosome, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia, Mixed Phenotype Acute Leukemia | 04/24 | 04/24 | | |
NCT04534634: Study of IFN-α Combined With CAR-T Cell Therapy in Relapsed and Refractory Acute Lymphoblastic Leukemia（R/R-ALL） |
|
|
| Recruiting | 2 | 60 | RoW | IFN-α combined with CAR-T cell therapy, CAR-T cell therapy | The First Affiliated Hospital of Soochow University | B-cell Acute Lymphoblastic Leukemia | 07/23 | 07/25 | | |
NCT06578546: Chemotherapy-free Regimen of Venetoclax, Azacitidine Plus Orebatinib (VAO Regimen) for Newly Diagnosed ph+ALL |
|
|
| Recruiting | 2 | 30 | RoW | Venetoclax, Azacitidine, Orebatinib | The First Affiliated Hospital of Soochow University | Ph-Positive Acute Lymphoblastic Leukemia | 02/25 | 02/26 | | |
NCT06394011: Study of VA Combined With HAAG Regimen in Newly Diagnosed Intermediate and High-risk AML Patients |
|
|
| Recruiting | 2 | 60 | RoW | venetoclax, azacitidine and HAAG regimen | The First Affiliated Hospital of Soochow University | Intermediate Risk Acute Myeloid Leukemia, High Risk Acute Myeloid Leukemia | 05/26 | 12/26 | | |
NCT06393985: Decitabine, Venetoclax and Blinatumomab for Maintenance Following HSCT in Patients With Ph-Negative B-ALL |
|
|
| Recruiting | 2 | 30 | RoW | Decitabine, venetoclax and blinatumomab | The First Affiliated Hospital of Soochow University | B-cell Acute Lymphoblastic Leukemia | 04/26 | 04/27 | | |
NCT06021210: Letermovir for the Prevention of CMV Infection in HSCT Recipients Based on the Outcome of mNGS |
|
|
| Recruiting | 2 | 80 | RoW | Letermovir Pill, Letermovir Tablets | The First Affiliated Hospital of Soochow University | CMV Infection, Hematopoietic Stem Cell Transplantation | 07/24 | 09/25 | | |
NCT06078306: CD19CD22 CAR-T Therapy in Patients With High-Risk B Acute Lymphoblastic Leukemia (B-ALL). |
|
|
| Recruiting | 2 | 20 | RoW | Azacitidine Injection, Azacitidine, Venetoclax, ABT-199, CD19CD22 CAR-T, GDC-0199 | The First Affiliated Hospital of Soochow University | B Acute Lymphoblastic Leukemia, Ph-Negative ALL, High Risk Acute Lymphoblastic Leukemia | 09/24 | 09/25 | | |
NCT05809167: Venetoclax+Azacytidine+Modified BUCY Conditioning Regimen for Acute Lymphoblastic Leukemia Undergoing Allo-HSCT |
|
|
| Recruiting | 2 | 55 | RoW | VEN+AZA+Modified BUCY | The First Affiliated Hospital of Soochow University | Allogeneic Hematopoietic Stem Cell Transplantation, Acute Lymphoblastic Leukemia | 01/25 | 01/26 | | |
NCT05823714: Venetoclax+Azacytidine+Modified BUCY Conditioning Regimen for Acute Myeloid Leukemia and Myelodysplastic Syndromes Undergoing Allo-HSCT |
|
|
| Recruiting | 2 | 70 | RoW | VEN+AZA+Modified BUCY | The First Affiliated Hospital of Soochow University | Allogeneic Hematopoietic Stem Cell Transplantation, Acute Myeloid Leukemia, Myelodysplastic Syndrome | 01/25 | 01/26 | | |
| Active, not recruiting | 1/2 | 196 | RoW | CAR T-cell therapy | The First Affiliated Hospital of Soochow University, Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd, The Second People's Hospital of Huai'an, Third Military Medical University | Acute Lymphoblastic Leukemia with Failed Remission | 08/24 | 12/25 | | |
NCT04351022: CD38-targeted Chimeric Antigen Receptor T Cell (CART) in Relapesd or Refractory Acute Myeloid Leukemia |
|
|
| Recruiting | 1/2 | 20 | RoW | CART-38 | The First Affiliated Hospital of Soochow University | Acute Myeloid Leukemia | 12/21 | 12/23 | | |
NCT04884984: Anti-CLL1 CAR T-cell Therapy in CLL1 Positive Relapsed/Refractory Acute Myeloid Leukemia (AML) |
|
|
| Recruiting | 1/2 | 20 | RoW | anti-CLL1 CART | The First Affiliated Hospital of Soochow University | Acute Myeloid Leukemia | 12/22 | 12/24 | | |
NCT03896854: CART-19 T Cell in CD19 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML) |
|
|
| Recruiting | 1/2 | 15 | RoW | CART-19 | Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd | Acute Myeloid Leukemia | 12/24 | 12/25 | | |
NCT04762485: Humanized CD7 CAR T-cell Therapy for r/r CD7+ Acute Leukemia |
|
|
| Recruiting | 1/2 | 20 | RoW | Humanized CD7 CAR-T cells | The First Affiliated Hospital of Soochow University, PersonGen BioTherapeutics (Suzhou) Co., Ltd. | T Lymphoblastic Leukemia/Lymphoma, Mixed Phenotype Acute Leukemia, Acute Myeloid Leukemia | 02/23 | 02/24 | | |
NCT04846439: Sequential Infusion of CD19 and BCMA CAR-T Cells to Improve PTR in Patients With AL |
|
|
| Recruiting | 1/2 | 20 | RoW | CAR-T infusion | The First Affiliated Hospital of Soochow University, Huai'an Second People's Hospital, The First Affiliated Hospital with Nanjing Medical University, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd | Platelet Transfusion Refractoriness, Acute Leukemia in Remission | 03/23 | 03/24 | | |
NCT05023707: Anti-FLT3 CAR T-cell Therapy in FLT3 Positive Relapsed/Refractory Acute Myeloid Leukemia |
|
|
| Recruiting | 1/2 | 5 | RoW | anti-FLT3 CAR-T | The First Affiliated Hospital of Soochow University, The First Affiliated Hospital with Nanjing Medical University, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Huai'an Second People's Hospital, PersonGen BioTherapeutics (Suzhou) Co., Ltd. | Acute Myeloid Leukemia | 06/23 | 06/25 | | |
NCT03275493: CD19 CAR-T Cells With CRS Suppression Technology for r/r CD19+ Acute Lymphoblastic Leukemia |
|
|
| Recruiting | 1/2 | 40 | RoW | CD19 CAR-T cells, CD19 CAR-T cells with CRS suppression technology | Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd, The First Affiliated Hospital of Soochow University | Acute Lymphoblastic Leukemia, CD19 Positive, Relapse, Refractory | 12/24 | 12/25 | | |
NCT03614858: CD19/CD22-targeted Chimeric Antigen Receptor Engineered T Cell (CART) in B-Cell Acute Lymphoblastic Leukemia. |
|
|
| Recruiting | 1/2 | 20 | RoW | CART-19/22 | Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd, The First Affiliated Hospital of Soochow University | Leukemia, B-cell | 12/24 | 12/25 | | |
NCT05732948: PD-1 Silent PSMA/PSCA Targeted CAR-T for the Treatment of Prostate Cancer |
|
|
| Recruiting | 1 | 12 | RoW | autologous T cells & cyclophosphamide | Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd, The First Affiliated Hospital of Soochow University | Prostate Cancer | 12/24 | 12/24 | | |
NCT06234904: Study of IBR733 Cell Injection in Acute Myeloid Leukemia |
|
|
| Not yet recruiting | 1 | 18 | RoW | IBR733 Cell Injection | Imbioray (Hangzhou) Biomedicine Co., Ltd., The First Affiliated Hospital of Soochow University | Acute Myeloid Leukemia | 02/25 | 08/25 | | |
